Skip to main navigation
Trevena, Inc. Trevena, Inc.
Menu
Menu
  • Home
  • About Trevena
    • About Trevena
    • Management
    • Board of Directors
    • Careers
  • Pipeline
    • Our Pipeline
    • Oliceridine injection
      • Moderate-to-Severe Acute Pain
      • Oliceridine Development
    • TRV250
    • TRV734
  • Platform
    • What is a Biased Ligand?
    • History of Biased Ligands
  • Investors
    • Investor Relations
    • Press Releases
    • Investor Presentations
    • Analyst Coverage
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
      • Quarterly Results
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
    • Investor FAQs
  • Publications
    • All Publications
  • Contact
    • Contact
    • Directions to Trevena
Biased Ligands. Better Drugs.

Investor Relations

  • Investor Relations
  • Press Releases
  • Investor Presentations
  • Analyst Coverage
  • Corporate Governance
  • Financials & Filings
  • Stock Information
  • Investor FAQs
 
Corporate Presentation

Shareholder Tools

  • Printed Materials
  • Email Alerts
  • Download Library
  • Print
  • Share
X
  • Facebook
  • Google+
  • LinkedIn
  • Twitter
  • RSS

Investor Presentations

21st Annual BIO CEO & Investor Conference

Feb 12, 2019 9:15 AM EST
Listen to webcast

Remind Me

  • About Trevena
  • Management
  • Board of Directors
  • Careers
  • Pipeline
  • Oliceridine injection
  • TRV250
  • TRV734
  • Platform
  • History of Biased Ligands
  • Investors
  • Press Releases
  • Investor Presentations
  • Analyst Coverage
  • Corporate Governance
  • Financials & Filings
  • Stock Information
  • Investor FAQs
  • Publications
  • Oliceridine injection
  • Biased Ligand
  • Contact
  • Directions
  • Follow Us:

Copyright © Trevena, Inc.